Get started
Author

Luther Gwaza

Observed names: Gwaza, Luther, L Gwaza, L. Gwaza, luther gwaza
Observed institutions: University of Zimbabwe, University of Cape Town, Utrecht University, World Health Organization, Agencia Española de Medicamentos y Productos Sanitarios, Medicines Evaluation Board
ORCID: 0000-0003-1880-1095
Observed ORCID: 0000-0003-1880-1095
OpenAlex ID: A5027756458
Position paper to facilitate patient access to radiopharmaceuticals: considerations for a suitable pharmaceutical regulatory framework
2024 · Aruna Korde, Marianne Patt, et al. · EJNMMI Radiopharmacy and Chemistry · 35
PDF
WHO collaborative registration procedure using stringent regulatory authorities’ medicine evaluation: reliance in action?
2022 · Alexandra Vaz, Mariana Roldão Santos, et al. · Expert Review of Clinical Pharmacology · 33
Needs‐driven talent and competency development for the next generation of regulatory scientists in Africa
2021 · Boitumelo Semete‐Makokotlela, Gugu N. Mahlangu, et al. · British Journal of Clinical Pharmacology · 33
PDF
Co-administration of a commonly used Zimbabwean herbal treatment (African potato) does not alter the pharmacokinetics of lopinavir/ritonavir
2013 · Luther Gwaza, Francesca Aweeka, et al. · International Journal of Infectious Diseases · 27
PDF
In vitro inhibitory effects of Hypoxis obtusa and Dicoma anomala on cyp450 enzymes and p-glycoprotein
2009 · Luther Gwaza, Alan R. Wolfe, et al. · African Journal of Pharmacy and Pharmacology · 21
Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing artemether/lumefantrine 20/120 mg tablets as prequalified by WHO
2012 · Luther Gwaza, John Gordon, et al. · European Journal of Clinical Pharmacology · 20
Comparison of free software platforms for the calculation of the 90% confidence interval of f2 similarity factor by bootstrap analysis
2020 · L. Noce, L. Gwaza, et al. · European Journal of Pharmaceutical Sciences · 19
Regulatory Requirements for the Development of Second-Entry Semisolid Topical Products in the European Union
2023 · Alfredo García-Arieta, John Gordon, et al. · Pharmaceutics · 15
PDF
Agitation Rate and Time for Complete Dissolution in BCS Biowaivers Based on Investigation of a BCS Biowaiver for Dexketoprofen Tablets
2015 · Alfredo Garcia-Arieta, John Gordon, et al. · Molecular Pharmaceutics · 15
Adjusted Indirect Treatment Comparison of the Bioavailability of WHO-Prequalified First-Line Generic Antituberculosis Medicines
2014 · L Gwaza, J Gordon, et al. · Clinical Pharmacology & Therapeutics · 11
Global Harmonization of Comparator Products for Bioequivalence Studies
2017 · Luther Gwaza, John Gordon, et al. · The AAPS Journal · 9
Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons
2015 · Luther Gwaza, John Gordon, et al. · European Journal of Clinical Pharmacology · 9
Perspectives on systematic capacity building in pharmaceutical regulation for regulators of medical products
2024 · Luther Gwaza, Andrew Chemwolo, et al. · Frontiers in Medicine · 7
PDF
Chiral bioanalytical methods in bioequivalence studies of intravenous vs. oral formulations of ibuprofen
2020 · Esperanza González‐Rojano, Julio Marcotegui, et al. · Chirality · 6
Interchangeability between First-Line Generic Antiretroviral Products Prequalified by WHO using Adjusted Indirect Comparisons
2016 · Luther Gwaza, John Gordon, et al. · Antiviral Therapy · 6
PDF
Adjusted indirect treatment comparisons of bioequivalence studies
2016 · Luther Gwaza · Utrecht University Repository (Utrecht University) · 5
Assessment of the interchangeability between generics
2016 · Luther Gwaza, John Gordon, et al. · Generics and Biosimilars Initiative Journal · 4
PDF
Importation and distribution of unregistered medicines in the public sector: similarities, differences, and shared challenges among Southern African Development Community (SADC) countries
2022 · Admire Nyika, Bernard Ngara, et al. · BMC Health Services Research · 3
PDF
Closing the gaps in the access to quality-assured medicines for global health: The case for oxytocin for postpartum haemorrhage
2025 · CC Lee, Luther Gwaza, et al. · Expert Review of Clinical Pharmacology · 2
Adapting the WHO Global Competency Framework for Regulators of Medicines: Implementation lessons from the South African Health Products Regulatory Authority
2026 · Goonaseelan Pillai, Boitumelo Semete-Makokotlela, et al.
PDF
A university‐certified course on dossier assessment for regulatory scientists in Africa—Reporting on our 5‐year experience
2026 · Stephanie Leigh, Boitumelo Semete‐Makokotlela, et al. · British Journal of Clinical Pharmacology
Scoping review protocol: Evaluation approaches for medicines marketing authorisation system performance
2026 · Luther Gwaza, Vulika Nangombe, et al. · OSF Preprints (OSF Preprints)
Scoping review protocol: Evaluation approaches for medicines marketing authorisation system performance
2026 · Nangombe, Vulika, Musonda, Mario MJ., et al.
Climate and Environmental Sustainability Across Healthcare to Inform Updates to WHO/FIP Good Pharmacy Practice (GPP)
2026 · Khalil, Hanan, Gwaza, Luther
The ‘WHO Global Competency Framework for Regulators of Medicines’ as an evaluation tool for training programmes
2025 · Tobias Siefen, Hanna Flamme, et al. · Journal of Public Health
PDF
Works count: 26
Citation count: 280
H-index: 10
I10-index: 10
Year
Topic
Type